Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2105-2115

  Best, Giles ^a   Thompson, Philip ^b   Tam, Constantine S ^b,c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

17p deletion; Fludarabine; fluorescence in situ hybridization; rituximab

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DNA; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; IBRUTINIB; IDELALISIB; LENALIDOMIDE; MESSENGER RNA; METHYLPREDNISOLONE; MITOXANTRONE; NAVITOCLAX; NUTLIN 3; OFATUMUMAB; OLIGONUCLEOTIDE; PROTEIN P53; RITUXIMAB;

ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME MUTATION; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; COMPLEMENT ACTIVATION; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIAGNOSTIC PROCEDURE; DNA BINDING; DNA DAMAGE; DRUG MEGADOSE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENOMIC INSTABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; IRRADIATION; LEUKEMIA REMISSION; LIMIT OF DETECTION; LYMPHOCYTE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; WILD TYPE;

GENE DELETION; GENES, P53; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION;

EID: 84867188772     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.692088     Document Type: Review

References (84)

1. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
2. Tam CS, Shanafelt TD, Wierda WG, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows signif cant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009;114:957-964.
3. Zenz T, Hoth P, Busch R, et al. TP53 mutations and outcome after f udarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial of the GCLLSG. Blood 2009;114(Suppl. 1): Abstract 1267.
4. Oscier D, Wade R, Davis Z, et al. Prognostic factors identif ed three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010;95:1705-1712.
5. Stilgenbauer S, Zenz T, Winkler D, et al. Genomic aberrations, VH mutation status and outcome after f udarabine and cyclo-phosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial. Blood 2008;112(Suppl. 1): Abstract 781.
6. Vogelstein B, Lane D, Levine AJ. Surf ng the p53 network. Nature 2000;408:307-310.
7. Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012;119:3668-3683.
8. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011;29:2223-2229.
9. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322-3329.
10. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in f udarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994-4001.
11. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012 Feb 2. [Epub ahead of print]
12. Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005;106:3175-3182. (Pubitemid 41565916)
13. Watanabe T, Hotta T, Ichikawa A, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994;84:3158-3165.
14. Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011;305:59-67.
15. Best OG, Gardiner AC, Davis ZA, et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 2009;23:212-214.
16. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323:720-724. (Pubitemid 20288941)
17. Mayr C, Speicher MR, Kof er DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742-751. (Pubitemid 43076401)
18. Grubor V, Krasnitz A, Troge JE, et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 2009;113:1294-1303.
19. Catovsky D, Richards S, Matutes E, et al. Assessment of f udarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230-239. (Pubitemid 47069536)
20. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to f udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
21. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008;111:5446-5456.
22. Haferlach C, Dicker F, Schnittger S, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007;21:2442-2451. (Pubitemid 350148886)
23. Pfeifer D, Pantic M, Skatulla I, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007;109:1202-1210. (Pubitemid 46220669)
24. Kay NE, Eckel-Passow JE, Braggio E, et al. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet 2010;203:161-168.
25. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799-804. (Pubitemid 350010635)
26. Zenz T, Vollmer D, Trbusek M, et al. TP53 mutation prof le in chronic lymphocytic leukemia: evidence for a disease specif c prof le from a comprehensive analysis of 268 mutations. Leukemia 2010;24:2072-2079.
27. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009;23:117-124.
28. el Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression Blood 1993;82:3452-3459. (Pubitemid 23356719)
29. Pekova S, Mazal O, Cmejla R, et al. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: analysis of 1287 diagnostic and 1148 follow-up CLL samples. Leuk Res 2011;35:889-898.
30. Chiaretti S, Tavolaro S, Marinelli M, et al. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression prof ling. Genes Chromosomes Cancer 2011;50:263-274.
31. Trbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011;29:2703-2708.
32. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet 1993;4:42-46. (Pubitemid 23165910)
33. Bromidge T, Johnson S, Howe D. Spectrum of p53 mutations in low-grade B-cell malignancies. Leukemia 2008;22:1071-1073. (Pubitemid 351689894)
34. Zainuddin N, Murray F, Kanduri M, et al. TP53 mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res 2011;35:272-274.
35. Dong HJ, Zhou LT, Zhu DX, et al. The prognostic signif cance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13). Ann Hematol 2011;90:709-717.
36. Mohr J, Helfrich H, Fuge M, et al. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood 2011;117:1622-1632.
37. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in f udarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589-2597.
38. Pettitt AR, Sherrington PD, Stewart G, et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814-822.
39. Johnson GG, Sherrington PD, Carter A, et al. A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res 2009;69:5210-5217.
40. Best OG, Gardiner AC, Majid A, et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008;22:1456-1459. (Pubitemid 352006096)
41. Mous R, Jaspers A, Luijks DM, et al. Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantif cation of p53 target gene induction. Leukemia 2009;23:1352-1355.
42. Trbusek M, Malcikova J, Smardova J, et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia 2006;20:1159-1161. (Pubitemid 43797312)
43. Tsimberidou AM, Tam C, Abruzzo LV, et al. Chemoimmunotherapy may overcome the adverse prognostic signif cance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373-380.
44. Schlette EJ, Admirand J, Wierda W, et al. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma 2009;50:1597-1605.
45. Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104:1428-1434. (Pubitemid 39166521)
46. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-4479.
47. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed f udarabine: results of a large international study. Blood 2002;99:3554-3561. (Pubitemid 34534522)
48. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008;26:5094-5100.
49. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. (Pubitemid 29430400)
50. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847. (Pubitemid 29430399)
51. Eichhorst BF, Busch R, Hopf nger G, et al. Fludarabine plus cyclophosphamide versus f udarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107:885-891. (Pubitemid 43156283)
52. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of f udarabine plus cyclophosphamide compared with f udarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793-798. (Pubitemid 350002879)
53. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the f udarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-980.
54. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, f udarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578-4584.
55. Parikh SA, Keating MJ, O'Brien S, et al. Frontline chemo-immunotherapy with f udarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011;118:2062-2068.
56. Heit W, Bunjes D, Wiesneth M, et al. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement ef ectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 1986;64:479-486. (Pubitemid 17184257)
57. Dyer MJ, Hale G, Hayhoe FG, et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: inf uence of antibody isotype. Blood 1989;73:1431-1439. (Pubitemid 19131883)
58. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody ef ector functions. Eur J Immunol 1993;23:1098-1104. (Pubitemid 23120172)
59. Rowan W, Tite J, Topley P, et al. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B-and T-lymphoma cell lines, and subsequent emergence of CD52-def cient cells. Immunology 1998;95:427-436. (Pubitemid 28505700)
60. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002;347:452-453. (Pubitemid 34851846)
61. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an ef ective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-3281. (Pubitemid 38525651)
62. Cortelezzi A, Pasquini MC, Gardellini A, et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 2009;23:2027-2033.
63. Fiegl M, Erdel M, Tinhofer I, et al. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol 2010;21:2410-2419.
64. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-5623.
65. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006;20:1441-1445. (Pubitemid 44084061)
66. Stilgenbauer S, Cymbalista F, Leblond V, et al. Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: interim analysis of a phase II study of the GCLLSG and FCGCLL/MW. Blood 2011; 118(Suppl. 1): Abstract 2854.
67. Ben-Bassat I, Raanani P, Gale RP. Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant 2007;39:441-446. (Pubitemid 46605201)
68. Schetelig J, T iede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia ef ect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003;21:2747-2753. (Pubitemid 46606321)
69. Khouri IF, Saliba RM, Admirand J, et al. Graft-versus-leukaemia ef ect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007; 137:355-363. (Pubitemid 46650260)
70. Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005;23:3433-3438.
71. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007;21:12-17. (Pubitemid 44921829)
72. Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116:2438-2447.
73. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-371. (Pubitemid 43939148)
74. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in f udarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-1755.
75. Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of f avopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009;27:6012-6018.
76. Lanasa MC, Andritsos L, Brown JR, et al. Interim analysis of EFC6663, a multicenter phase 2 study of alvocidib (f avopiridol), demonstrates clinical responses among patients with f udarabine refractory CLL. Blood 2010;116(Suppl. 1): Abstract 58.
77. Chanan-Khan A, Miller KC, Musial L, et al. Clinical effcacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24:5343-5349. (Pubitemid 46623164)
78. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-5297.
79. Ferrajoli A, Keating MJ, Wierda WG, et al. Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) carrying unfavorable chromosomal abnormalities. Blood 2007; 110(Suppl. 1): Abstreact 754.
80. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-af nity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11:1149-1159.
81. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488-496.
82. Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011;118:4313-4320.
83. Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;116(Suppl. 1): Abstract 55.
84. O'Brien S, Burger JA, Blum KA, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic Lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study. Blood 2011; 118(Suppl. 1): Abstract 983.